

Special Issue

People's Perception on COVID-19 Vaccine and Its Accessibility

Message from the Guest Editors

A strategic vision for pandemic control across different countries must include all the potential gains from population-level immunity—not only health improvements and the prevention of mortality and morbidity but also strong psychosocial and economic protection from further catastrophic consequences. Vaccine hesitancy is a reality but needs to be addressed and minimized, and there are several factors associated with it globally. However, to overcome this critical challenge during the management of the pandemic, it is the responsibility of not only public health practitioners but also the global science community, influential and popular individuals, and political leaders to raise public awareness through health-promotion campaigns. Emerging scientific evidence from population-level vaccinations will accelerate the global promotion of vaccination. In this Special Issue, we are calling for contributors from every corner of the world to disseminate research activities related to COVID-19 vaccine hesitancy and vaccine-shortage issues.

Guest Editors

Dr. Russell Kabir

School of Allied Health, Faculty of Medical Sciences, Anglia Ruskin University, Bishop Hall Lane, Chelmsford CM1 1SQ, UK

Dr. Ali Davod Parsa

School of Allied Health, Faculty of Health, Education, Medicine and Social Care, Anglia Ruskin University, Cambridge CB11PT, UK

Deadline for manuscript submissions

closed (28 February 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/99148

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).